| Literature DB >> 21845152 |
M Margaret Pratt1, Kaarthik John, Allan B MacLean, Senait Afework, David H Phillips, Miriam C Poirier.
Abstract
Polycyclic aromatic hydrocarbons (PAHs) are combustion products of organic materials, mixtures of which contain multiple known and probable human carcinogens. PAHs occur in indoor and outdoor air, as well as in char-broiled meats and fish. Human exposure to PAHs occurs by inhalation, ingestion and topical absorption, and subsequently formed metabolites are either rendered hydrophilic and excreted, or bioactivated and bound to cellular macromolecules. The formation of PAH-DNA adducts (DNA binding products), considered a necessary step in PAH-initiated carcinogenesis, has been widely studied in experimental models and has been documented in human tissues. This review describes immunohistochemistry (IHC) studies, which reveal localization of PAH-DNA adducts in human tissues, and semi-quantify PAH-DNA adduct levels using the Automated Cellular Imaging System (ACIS). These studies have shown that PAH-DNA adducts concentrate in: basal and supra-basal epithelium of the esophagus, cervix and vulva; glandular epithelium of the prostate; and cytotrophoblast cells and syncitiotrophoblast knots of the placenta. The IHC photomicrographs reveal the ubiquitous nature of PAH-DNA adduct formation in human tissues as well as PAH-DNA adduct accumulation in specific, vulnerable, cell types. This semi-quantative method for PAH-DNA adduct measurement could potentially see widespread use in molecular epidemiology studies.Entities:
Keywords: DNA damage; PAH-DNA adducts; human tissues; immunoassay; immunohistochemistry; molecular epidemiology; semi-quantitation
Mesh:
Substances:
Year: 2011 PMID: 21845152 PMCID: PMC3155323 DOI: 10.3390/ijerph8072675
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Figure 1Standard curve consisting of cultured human keratinocytes exposed to 0, 0.25, 0.50, 0.75, or 1.00 μM BPDE for 1 h.
Figure 2Human esophageal biopsy samples collected in 1987 and 1994 then stained and analyzed up to 17 years later by BPDE-DNA IHC/ACIS.
Figure 3Representative human prostate, cervix and vulvar tissue biopsies evaluated for PAH-DNA adducts*.
* Tissues stained with hematoxylin (A, D and G, respectively) to obtain a count of total nuclei; immunogen (BPDE-DNA)-absorbed serum (B, E and H, respectively) to demonstrate specificity of the serum; and specific BPdG-DNA serum (C, F and I, respectively) to show the presence of PAH-DNA adducts. The tic marks indicate 10 μm intervals and are for the purpose of image localization.
Comparison of PAH-DNA adduct values in human tissues by IHC/ACIS.
| Tissue | Number of Subjects | PAH-DNA adducts/108 nucleotides
| Cell type with highest PAH-DNA Adducts | |||
|---|---|---|---|---|---|---|
| Non-detect subjects | Low | High | Cells/subject | |||
| Esophagus | 10 | 1 | NA | NA | 1,000–8,000 | Basal epithelial |
| Prostate | 23 | 2 | 8 | 2,214 | 200–300 | Ductal epithelium |
| Cervix | 75 | 3 | 20 | 191 | 72–2,200 | Basal epithelial |
| Vulva | 10 | 1 | 20 | 206 | 120–747 | Basal epithelial |
| Placenta | 14 | 0 | 49 | 312 | 200–400 | Cytotrophoblast and Syncytiotrophoblast |
NA = not assayed; the standard curve quantitation was not performed with the esophagus samples, but was performed with the prostate, cervix, vulva and placenta samples.
Shows the LOD for each assay. The LOD for the placenta study was 20 adducts/108 nucleotides but the lowest human value was 49.
Figure 4PAH-DNA adducts/108 nucleotides (mean ± SD) as determined by IHC/ACIS in 3–4 different areas of vulvar basal epithelium in each of 10 individuals.
Figure 5Overview of human placenta tissue architecture and example of scored tissue region.